UBS Group Reiterates “Buy” Rating for Clinigen Group (CLIN)
Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reaffirmed by investment analysts at UBS Group in a research note issued on Thursday, www.digitallook.com reports. They presently have a GBX 1,160 ($15.11) price target on the stock. UBS Group’s price target points to a potential upside of 37.20% from the stock’s current price.
Other equities analysts also recently issued research reports about the stock. Peel Hunt reissued a “buy” rating on shares of Clinigen Group in a research note on Wednesday, August 1st. Numis Securities reissued a “buy” rating on shares of Clinigen Group in a research note on Tuesday, July 17th. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of GBX 1,243.83 ($16.20).
Shares of CLIN opened at GBX 845.50 ($11.01) on Thursday. Clinigen Group has a 1 year low of GBX 751.50 ($9.79) and a 1 year high of GBX 1,187 ($15.46).
Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.
Further Reading: What Does Beta Mean In Stock Selection
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.